In Vitro Activities of Ceftobiprole and Doripenem Tested against Frequently Encountered Aerobic and Facultative Gram-Positive and Gram-Negative Bacterial Pathogens Isolated from Patients in Canadian Hospitals in 2007
BACKGROUND: In 2008, ceftobiprole was approved by Health Canada for the treatment of patients with complicated skin and skin structure infections including diabetic foot infections; approval of ceftobiprole by the United States Food and Drug Administration is pending. Doripenem is currently under re...
Saved in:
Main Authors: | James A Karlowsky, Mel DeCorby, Daryl J Hoban, George G Zhanel |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2009-01-01
|
Series: | Canadian Journal of Infectious Diseases and Medical Microbiology |
Online Access: | http://dx.doi.org/10.1155/2009/183843 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Mutant Prevention Concentrations of Doripenem and Meropenem Alone and in Combination with Colistin (Polymyxin E), Levofloxacin and Tobramycin in Pseudomonas aeruginosa
by: George G Zhanel, et al.
Published: (2009-01-01) -
Characterization of Pseudomonas aeruginosa Isolates Obtained from Patients in Canadian Hospitals: Results of the CANWARD 2007 Study
by: Andrew Walkty, et al.
Published: (2009-01-01) -
Prevalence of Antimicrobial-Resistant Pathogens in Canadian Hospitals: Results of the Canadian Ward Surveillance Study (CANWARD 2007)
by: George G Zhanel, et al.
Published: (2009-01-01) -
Pharmacodynamic Profiling of Antimicrobials against Gram-negative Respiratory Isolates from Canadian Hospitals
by: Rebecca A. Keel, et al.
Published: (2011-01-01) -
Environmental microbial communications in gram-positive and gram-negative bacteria
by: P. Srikanth, et al.
Published: (2023-11-01)